T1	Participants 83 131	patients with advanced nasopharyngeal carcinoma:
T2	Participants 281 335	patients with advanced nasopharyngeal carcinoma (NPC).
T3	Participants 344 410	Two hundred patients with stage III/IV NPC were randomly allocated
T4	Participants 420 474	treatment group (N=100) and the control group (N=100).
T5	Participants 1486 1512	patients with advanced NPC
